Avacta appoints Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division
Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affi...
Continue Reading →
